Kenneth McCall, BSPharm, PharmD Associate Professor UNE

Transcription

1 Kenneth McCall, BSPharm, PharmD Associate Professor UNE

2 Objectives Discuss the gap between current rates and Healthy People 2020 goals for vaccinations. Categorize each of the CDC recommended flu vaccines based upon live/inactivated, route, prep., and storage. Apply new ACIP recommendations and FDA approved indications for pneumococcal, zoster and influenza vaccines.

3 3

4 1% What is the Healthy People 2020 goal for annual influenza vaccination for adults 65 and older? 9% % 87% 2. 90% 3% 3. 70% 4. 50%

5 2014 Recommended Adult Immunization Schedule, by vaccine and age group

6 Vaccines that might be indicated for adults based on medical and other indications

7

8 8

9

10 ACIP Recommendations Influenza Season For , U.S.-licensed influenza vaccines will contain the same vaccine virus strains as those in the vaccine. All persons aged 6 months should receive influenza vaccine annually. When immediately available, LAIV should be used for healthy children aged 2 through 8 years who have no contraindications or precautions. If LAIV is not immediately available, IIV should be used. Persons who care for severely immunosuppressed persons who require a protective environment should not receive LAIV, or should avoid contact with such persons for 7 days after receipt, given the theoretical risk for transmission of the live attenuated vaccine virus. Persons who report having had reactions to egg involving such symptoms as angioedema, respiratory distress, lightheadedness, or recurrent emesis; or who required epinephrine or another emergency medical intervention, may receive RIV3 if they are aged 18 through 49 years and there are no other contraindications. MMWR August 15, 2014 / 63(32);

11 US Influenza Vaccines: 2014 Vaccine Age Group Dosage Schedule Route Inactivated, Trivalent Standard Dose Inactivated, Quadrivalent Standard Dose Inactivated, Mammalian Trivalent Standard Dose Inactivated, Recombinant Trivalent Standard Dose Inactivated, Trivalent High Dose Inactivated, Trivalent Intra-dermal Live, Quadrivalent Intranasal 6-35 mos 0.25 ml 1 or 2 shots IM 3-8 years 0.5 ml 1 or 2 shots IM >9 years 0.5 ml 1 shot IM 3-8 years 0.5 ml 1 or 2 shots IM >9 years 0.5 ml 1 shot IM >18 years 0.5 ml 1 shot IM years 0.5 ml 1 shot IM >65 years 0.5 ml 1 shot IM years 0.1 ml 1 shot ID 2-8 years 0.2 ml 1 or 2 Nasal 9-49 years 0.2 ml 1 dose Nasal

12 New Influenza Vaccines: 2014 Fluarix (GlaxoSmithKline) inactivated, quadrivalent vaccine FDA approved December 2012 People ages 3 years and older Fluzone (Sanofi Pasteur) inactivated, quadrivalent vaccine. FDA approved March 2013 People ages 6 months and older Flumist Quadrivalent (MedImmune) live, attenuated, quadrivalent vaccine FDA approved March, 2012 People ages 2 through 49 years Flucelvax (Novartis) trivalent inactivated vaccine grown in mammalian cells. FDA approved November, 2012 Adults 18 years and older Doesn t list severe allergic reaction to egg protein in the contraindications Flublok (Protein Sciences Corp.) inactivated, trivalent, recombinant vaccine. FDA approved March 2013 People ages 6 months and older Doesn t list severe allergic reaction to egg protein in the contraindications

13 Which of the following was the predominant flu strain of ? 2% 1. Type B strain in trivalent vaccine 0% 98% 0% 2. Type B strain not in trivalent vaccine 3. Type A H1N1 strain 4. Type A H3N2 strain

14 14

15 New Influenza Vaccines: Flumist Quadrivalent (MedImmune) live attenuated vaccine which contains two type A and two type B strains FDA approved March, 2012 People ages 2 through 49 years

16

17

18

19

20 Live Attenuated Influenza Vaccine Indication Healthy people 2 through 49 years of age Contraindications Pregnant women People who have long-term health problems with: heart disease kidney or liver disease lung disease metabolic disease, such as diabetes asthma anemia, and other blood disorders Anyone with a weakened immune system Severe egg allergy I pick my nose! 20

21 Administration Flumist : 0.1-mL dose in each nostril Intranasal 21

22 Which of the following patients is a candidate for the live influenza vaccine? 2% yo man with severe egg allergy 95% 0% 2% 2% yo healthy woman yo man with diabetes yo healthy man yo pregnant woman

23 Which of the following influenza vaccine(s) is/are preferred for a healthy 7-year-old boy. 20% 1. Fluzone 20% 20% 20% 20% 2. Fluzone ID 3. Flumist 4. Flucelvax 5. 1 and 2

24 24

25 Methods: Multicenter, randomized, double-blind controlled study HD vaccine (60 mcg of hemagglutinin per strain): N=15,991 SD vaccine (15 mcg of hemagglutinin per strain): N=15,998 Adults 65 years and older. Nursing home residents and immunocompromised persons were excluded. N Engl J Med 2014;371:

26 Occurrence of laboratory-confirmed influenza following administration of HD and SD influenza vaccines Number of cases All Strains A/H1N1 A/H3N2 B SD HD N Engl J Med 2014;371:

27 Efficacy of HD Vaccine vs. Standard Dose against Laboratory Confirmed Influenza of Any Type Number (%) of cases IV3-HD: 228/15,990 (1.4%) IV3-SD: 301/15,993 (1.9%) Relative Efficacy (95% CI) 24.2% (9.7% 36.5%) Absolute Efficacy 0.5% Number Needed to Treat 200

28 Administration Fluzone HD : 0.5-mL dose IM - deltoid 1 inch, 25 gauge needle 28

29 Which of the following statements is FALSE when comparing the efficacy of Fluzone HD to Fluzone in adults 65 years or older? 25% 25% 25% 25% 1. The relative efficacy of Fluzone HD is 24% > than Fluzone 2. The absolute efficacy of Fluzone HD is 0.5% > than Fluzone 3. These results apply to nursing home patients 4. The NNT is 200 to avoid one additional case of influenza

30

31 Influenza Vaccines and Age Indications Vaccine Age Indications 6-23m 2-3y 3-17y 18-49y 50-64y 65+y Inactivated Trivalent (Fluzone, Afluria, Fluvirin ) Inactivated Quadrivalent (Fluarix, FluLaval, Fluzone ) Inactivated Mammalian Trivalent (Flucelvax ) Recombinant Influeza Vaccine, Trivalent (FluBlok ) Live Quadrivalent (Flumist ) Intradermal Trivalent (Fluzone ID ) Preferred: Healthy 2-8 yrs High Dose Trivalent (Fluzone HD ) Indicated for those meeting age requirements and without contraindications

32 Influenza Vaccine Indications Vaccine Indication Inactivated Trivalent (Fluzone, Afluria, Fluvirin ) Inactivated Quadrivalent (Fluarix ) Inactivated Mammalian & Recombinant Trivalent (FluBlok, Flucelvax ) Live Quadrivalent (Flumist ) Pregnant Severe Egg Allergy Patients with high risk medical conditions** Intradermal Trivalent (Fluzone ID ) High Dose Trivalent (Fluzone HD ) Indicated for individuals meeting age requirements. contraindicated **Patients with high risk medical conditions: including immunocompromised, chronic cardiovascular disease, Diabetes Mellitus, pulmonary disease, or metabolic disease.

33

34

35 Pneumococcal Vaccines Pneumovax 23 (PPSV23, pneumococcal polysaccharide vaccine) Prevnar 13 (PCV13, pneumococcal conjugate vaccine)

36

37 ACIP Recommendations on Pneumococcal Vaccinations in Adults

38 ACIP Recommendations on Pneumococcal Vaccinations in Adults Both PCV13 and PPSV23 should be administered routinely in series to all adults aged 65 years. Pneumococcal vaccine-naïve persons. Adults aged 65 years who have not previously received pneumococcal vaccine or whose previous vaccination history is unknown should receive a dose of PCV13 first, followed by a dose of PPSV23. The dose of PPSV23 should be given 6 12 months after a dose of PCV13. If PPSV23 cannot be given during this time window, the dose of PPSV23 should be given during the next visit. The two vaccines should not be coadministered, and the minimum acceptable interval between PCV13 and PPSV23 is 8 weeks. MMWR September 19, 2014 / 63 (37)

39 ACIP Recommendations on Pneumococcal Vaccinations in Adults Previous vaccination with PPSV23. Adults aged 65 years who have previously received 1 doses of PPSV23 also should receive a dose of PCV13 if they have not yet received it. A dose of PCV13 should be given 1 year after receipt of the most recent PPSV23 dose. For those for whom an additional dose of PPSV23 is indicated, this subsequent PPSV23 dose should be given 6 12 months after PCV13 and 5 years after the most recent dose of PPSV23. The recommendations for routine PCV13 use among adults aged 65 years will be reevaluated in 2018 and revised as needed. ACIP recommendations for routine use of PCV13 in adults aged 19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leak, or cochlear implants remain unchanged. MMWR September 19, 2014 / 63 (37)

40 Pneumococcal vaccine-naïve persons aged > 65 years *minimum interval between sequential administration of PCV13 and PPSV23 is 8 weeks; PPSV23 can be given later than 6-12 months after PCV13 if this window is missed.

41 Persons who previously received PPSV23 at age > 65 years *minimum interval between sequential administration of PCV13 and PPSV23 is 8 weeks; PPSV23 can be given later than 6-12 months after PCV13 if this window is missed.

42 Persons who previously received PPSV23 before age 65 years who are now aged > 65 years

43

44

45 PPSV23 (Pneumovax ) ACIP: Pneumococcal. MMWR. Accessed 30 July Age Who receives the vaccine? 65 years old Vaccination history unclear or never received vaccine before Revaccinate: If patient received vaccine before the age of 65 and it has been 5 years since administration 2-64 years old Chronic cardiovascular disease (CHF, cardiomyopathies) Chronic pulmonary disease (COPD) Diabetes mellitus Alcoholism Chronic liver disease Cerebrospinal fluid leaks years old Cigarette smokers Asthma Re-vaccination after 5 years if: (see figure 1 on next slide) functional or anatomic asplenia Immunocompromising conditions Chronic kidney disease

46 Administration Pneumovax & Prevnar : 0.5 ml dose 1 inch, 25 gauge needle Intramuscular (IM) - deltoid CDC: Vaccines and Immunizations. Pneumococcal Disease. Accessed 30 July

47 1% What is the Healthy People 2020 goal for pneumococcal vaccination for adults 65 and older? 9% % 87% 2. 90% 3% 3. 70% 4. 50%

48 A 65-year-old man who is pneumonia vaccine naïve. What pneumonia vaccine(s) is/are recommended? 25% 1. Pneumovax only 25% 25% 25% 2. Prevnar only 3. Both; Pneumovax prior to Prevnar 4. Both; Prevnar prior to Pneumovax

49

50 Clinical Presentation of Herpes Zoster 1 3 Herpes Zoster Rash Follows a Dermatomal Distribution Phototake. Phototake. Dr. P. Marazzi / Photo Researchers, Inc. Prodrome Acute HZ Rash Evolution of Rash Complications? Abnormal Skin Sensations Headache Photophobia Malaise Unilateral Dermatomal Rash Cessation of New Vesicles Maculopapules/Vesicles Pustulation Altered Sensitivity to Touch Scabbing Unbearable Itching Cutaneous Healing Pain (varying severity) Neurologic Cutaneous Ophthalmic Visceral (rare) Aching, burning, stabbing, shock-like 1. Oxman MN. In: Arvin AM et al, eds. Varicella-Zoster Virus: Virology and Clinical Management. Cambridge, UK: Cambridge University Press; 2000: Weaver BA. J Am Osteopath Assoc. 2007;107(suppl 1):S2 S7. 3. Harpaz R et al. MMWR Morb Mortal Wkly Rep. 2008;57(RR-5):1 30.

51 ZOSTAVAX (Zoster Vaccine Live) 51

52 Zoster Vaccine Indication ACIP recommends routine vaccination of all persons aged >60 years with 1 dose of zoster vaccine. NEW FDA LABELING: ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. Persons who report a previous episode of zoster and persons with chronic medical conditions can be vaccinated unless those conditions are contraindications or precautions. Zoster vaccination is not indicated to treat acute zoster. Zostavax [package insert]. Whitehouse Station, NJ: Merck; April Recommendations of the Advisory Committee on Immunization Practices (ACIP) 52

53 Efficacy of ZOSTAVAX (Zoster Vaccine Live) on Incidence of Herpes Zoster in Adults Aged Years Based on the results of the ZOSTAVAX Efficacy and Safety Trial (ZEST) 1,a Number of Zoster Cases 70 % in subjects [95% CI: 54 81] Placebo (n=11,228) ZOSTAVAX (n=11,211) a Study Design for ZEST: In the ZOSTAVAX Efficacy and Safety Trial, efficacy was evaluated in a placebocontrolled, double-blind study of ZOSTAVAX. 22,439 subjects 50 to 59 years of age were randomized to receive a single dose of either ZOSTAVAX (n=11,211) or placebo (n=11,228) and were monitored for the occurrence of shingles for a median of 1.3 years postvaccination (range, 0 to 2 years). 1. Schmader KE et al. Clin Infect Dis. 2012;54:

54 ACIP Recommendations for Use of ZOSTAVAX (Zoster Vaccine Live): Adults Aged Years 1 ZOSTAVAX is FDA approved for use in patients 50 years and older The ACIP has clarified that despite the absence of an ACIP recommendation, providers may consider the following factors when deciding whether to administer ZOSTAVAX among certain patients aged years: Adults Aged Years With: Preexisting chronic pain, severe depression, or other comorbid conditions Inability to tolerate treatment medications because of hypersensitivity or interactions with other chronic medications Occupational considerations Consider Vaccination ACIP=Advisory Committee on Immunization Practices. 1. Harpaz R et al. MMWR. 2011;60:1528.

55 Administration Zostavax: 0.65-mL dose (reconstituted) SQ upper, outer tricep 5/8 inch, 25 gauge needle 55

56 Which of the following statements is FALSE regarding the administration of Zostavax by trained individuals in Maine? 25% 1. A pharmacist or intern may administer Zostavax to a 61-year-old patient 25% 2. A pharmacist or intern may administer Zostavax to a 51-year-old patient 25% 3. Interns can not administer Zostavax 4. A pharmacist may administer Zostavax 25% to a 41-year-old patient pursuant to a Rx

57